Skip to main content
Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer
Drug guidance

Alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

Condition

Cancer

Respiratory

4 June 2025

Guidance Recommendations

Back to top